Meta-Analysis

Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis

Department of Thoracic Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention & Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China

Department of Oncology, Jining No.1 People's Hospital, Jining, Shandong, 272000, China

‡These authors contributed equally to this work

Search for more papers by this author

Wenjie Liu‡

‡These authors contributed equally to this work

Search for more papers by this author

Sipei Zhang‡

Department of Pharmacy, Tianjin Chest Hospital, Tianjin, 300222, China

‡These authors contributed equally to this work

Search for more papers by this author

Peng Chen

*Author for correspondence:

E-mail Address: chenpengdoc@sina.com

Search for more papers by this author

Published Online:23 Jan 2023https://doi.org/10.2217/imt-2022-0140

View article

Abstract

Aims: To clarify the relationship between the potency of dual blockade of PD-1 or its ligand (PD-L1) plus CTLA-4 and patients with different clinical characteristics with solid tumors, the authors performed this meta-analysis. Patients & methods: 12 randomized clinical trials containing 7056 patients were included after the literature was filtered. Results: Dual blockade substantially enhanced overall survival and progression-free survival compared with standard of care, especially in patients aged <65 years old, those 65–74 years old, those with a smoking history, members of the White population and those with a high tumor mutation burden. Conclusion: Dual blockade therapy significantly improved patient survival outcomes. Age, smoking history, race and tumor mutation burden might be used to predict the potency of dual blockade therapy in solid tumors.

Plain language summary

PD-1/PD-L1 plus CTLA-4 inhibitors therapy has been shown to be effective in many cancers. This meta-analysis found a correlation between efficacy and the characteristics of patients. Several datasets were used to screen the articles. Review Manager 5.3 was used for statistical analysis. A total of 7056 patients from 12 randomized, controlled trials were included. It was found that significant benefits were obtained by dual inhibitors. Their efficacy was correlated with patient age, smoking history, race and tumor mutation burden. These findings are important for clinical medication decisions.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Emens LA, Ascierto PA, Darcy PK et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer 81, 116–129 (2017).
Medline CASGoogle Scholar
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480(7378), 480–489 (2011).
Medline CASGoogle Scholar
3. Giroux Leprieur E, Dumenil C, Julie C et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges. Eur. J. Cancer 78, 16–23 (2017).
MedlineGoogle Scholar
4. Pai-Scherf L, Blumenthal GM, Li H et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist 22(11), 1392–1399 (2017).
Medline CASGoogle Scholar
5. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11(1), 3801 (2020).
Medline CASGoogle Scholar
6. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29–39 (2018).
Medline CASGoogle Scholar
7. Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
Medline CASGoogle Scholar
8. Rotte A, D'Orazi G, Bhandaru M. Nobel committee honors tumor immunologists. J. Exp. Clin. Cancer Res. 37(1), 262 (2018).
Medline CASGoogle Scholar
9. Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann. Oncol. 29(1), 71–83 (2018).
Medline CASGoogle Scholar
10. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013, 857519 (2013).
MedlineGoogle Scholar
11. Guha P, Heatherton KR, O'Connell KP, Alexander IS, Katz SC. Assessing the future of solid tumor immunotherapy. Biomedicines 10(3), 655 (2022). • Review summarizing the outcomes in solid tumor patients receiving different kinds of immunotherapies.
Medline CASGoogle Scholar
12. Goldman JW, Dvorkin M, Chen Y et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 22(1), 51–65 (2021).
Medline CASGoogle Scholar
13. Hodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 17(11), 1558–1568 (2016).
Medline CASGoogle Scholar
14. Hodi FS, Chiarion-Sileni V, Gonzalez R et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19(11), 1480–1492 (2018).
Medline CASGoogle Scholar
15. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
Medline CASGoogle Scholar
16. Powles T, van der Heijden MS, Castellano D et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 21(12), 1574–1588 (2020).
Medline CASGoogle Scholar
17. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377(14), 1345–1356 (2017).
Medline CASGoogle Scholar
18. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4), 707–723 (2017).
Medline CASGoogle Scholar
19. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19(3), 133–150 (2019).
Medline CASGoogle Scholar
20. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity 52(1), 17–35 (2020). • Review defining ten key challenges facing cancer immunotherapy.
Medline CASGoogle Scholar
21. Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr. Oncol. 25(4), e324–e334 (2018).
Medline CASGoogle Scholar
22. Thorn M, Guha P, Cunetta M et al. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. Cancer Gene Ther. 23(6), 188–198 (2016).
Medline CASGoogle Scholar
23. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14(4), 847–856 (2015).
Medline CASGoogle Scholar
24. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity 48(3), 434–452 (2018).
Medline CASGoogle Scholar
25. Bubendorf L, Conde E, Cappuzzo F et al. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens. Cancer Cytopathol. 128(12), 928–938 (2020).
Medline CASGoogle Scholar
26. Girolami I, Pantanowitz L, Barberis M et al. Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma. J. Oral Pathol. Med. 50(9), 864–873 (2021).
Medline CASGoogle Scholar
27. Pang JB, Castles B, Byrne DJ et al. SP142 PD-L1 scoring shows high interobserver and intraobserver agreement in triple-negative breast carcinoma but overall low percentage agreement with other PD-L1 clones SP263 and 22C3. Am. J. Surg. Pathol. 45(8), 1108–1117 (2021).
MedlineGoogle Scholar
28. Torlakovic E, Lim HJ, Adam J et al. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod. Pathol. 33(1), 4–17 (2020).
MedlineGoogle Scholar
29. Prasad V, Addeo A. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann. Oncol. 31(9), 1112–1114 (2020).
Medline CASGoogle Scholar
30. Ferris RL, Haddad R, Even C et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann. Oncol. 31(7), 942–950 (2020).
Medline CASGoogle Scholar
31. Hellmann MD, Paz-Ares L, Bernabe Caro R et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381(21), 2020–2031 (2019).
Medline CASGoogle Scholar
32. Owonikoko TK, Park K, Govindan R et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J. Clin. Oncol. 39(12), 1349–1359 (2021).
Medline CASGoogle Scholar
33. Lee HT, Lee SH, Heo YS. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules 24(6), 1190 (2019).
MedlineGoogle Scholar
34. Chen EX, Jonker DJ, Loree JM et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 6(6), 831–838 (2020).
MedlineGoogle Scholar
35. Baas P, Scherpereel A, Nowak AK et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397(10272), 375–386 (2021).
Medline CASGoogle Scholar
36. Doki Y, Ajani JA, Kato K et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386(5), 449–462 (2022).
Medline CASGoogle Scholar
37. Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378(14), 1277–1290 (2018). •• The first published large-scale, randomized, controlled trial that explored the efficacy of double blockade therapy in solid tumors.
Medline CASGoogle Scholar
38. Paz-Ares L, Ciuleanu TE, Cobo M et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22(2), 198–211 (2021).
Medline CASGoogle Scholar
39. Peters S, Scherpereel A, Cornelissen R et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. 33(5), 488–499 (2022).
Medline CASGoogle Scholar
40. Planchard D, Reinmuth N, Orlov S et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann. Oncol. 31(5), 609–618 (2020).
Medline CASGoogle Scholar
41. Rizvi NA, Cho BC, Reinmuth N et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 6(5), 661–674 (2020).
MedlineGoogle Scholar
42. Scheper W, Kelderman S, Fanchi LF et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25(1), 89–94 (2019).
Medline CASGoogle Scholar
43. Li J, Byrne KT, Yan F et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49(1), 178–193.e7 (2018).
Medline CASGoogle Scholar
44. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73(12), 3591–3603 (2013).
Medline CASGoogle Scholar
45. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 381(9868), 752–762 (2013).
MedlineGoogle Scholar
46. Isaacs J, Antonia S, Clarke J. Immune checkpoint inhibitors in the aged. Curr. Oncol. Rep. 23(10), 115 (2021).
MedlineGoogle Scholar
47. Kasherman L, Siu D, Lee K et al. Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: a meta-analysis. J. Geriatr. Oncol. 11(3), 508–514 (2020).
MedlineGoogle Scholar
48. Petrelli F, Inno A, Ghidini A, Gori S, Bersanelli M. Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years. Cancer Immunol. Immunother. 70(6), 1777–1780 (2021).
Medline CASGoogle Scholar
49. Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: immune aging & checkpoint inhibitors. J. Geriatr. Oncol. 8(3), 229–235 (2017).
MedlineGoogle Scholar
50. Bhandari S, Gill AS, Perez CA, Jain D. Management of immunotherapy toxicities in older adults. Semin. Oncol. 45(4), 226–231 (2018).
Medline CASGoogle Scholar
51. Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology 60(2), 130–137 (2014).
Medline CASGoogle Scholar
52. Daste A, Domblides C, Gross-Goupil M et al. Immune checkpoint inhibitors and elderly people: a review. Eur. J. Cancer 82, 155–166 (2017).
Medline CASGoogle Scholar
53. Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat. Rev. 45, 30–37 (2016).
Medline CASGoogle Scholar
54. Zheng SY, Cui HJ, Duan H et al. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis. Clin. Transl. Oncol. 22(7), 1146–1154 (2020).
Medline CASGoogle Scholar
55. Klein SL, Flanagan KL. Sex differences in immune responses. Nat. Rev. Immunol. 16(10), 626–638 (2016).
Medline CASGoogle Scholar
56. Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun. Rev. 11(6-7), A479–A485 (2012).
Medline CASGoogle Scholar
57. Lin PY, Sun L, Thibodeaux SR et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J. Immunol. 185(5), 2747–2753 (2010).
Medline CASGoogle Scholar
58. Wallach JD, Sullivan PG, Trepanowski JF, Steyerberg EW, Ioannidis JP. Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. BMJ 355, i5826 (2016).
MedlineGoogle Scholar
59. Roden AC, Moser MT, Tri SD et al. Augmentation of T cell levels and responses induced by androgen deprivation. J. Immunol. 173(10), 6098–6108 (2004).
Medline CASGoogle Scholar
60. Liva SM, Voskuhl RR. Testosterone acts directly on CD4⁺ T lymphocytes to increase IL-10 production. J. Immunol. 167(4), 2060–2067 (2001).
Medline CASGoogle Scholar
61. Heppt MV, Heinzerling L, Kähler KC et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur. J. Cancer 82, 56–65 (2017).
Medline CASGoogle Scholar
62. Yao J, Wang Z, Sheng J et al. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a two-center retrospective study. Int. Immunopharmacol. 89(Pt A), 107033 (2020).
Medline CASGoogle Scholar
63. Olio FG, Maggio I, Massucci M et al. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors – a systematic review and meta-analysis of real world data. Lung Cancer 145, 95–104 (2020).
MedlineGoogle Scholar
64. Tang B, Yan X, Sheng X et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J. Hematol. Oncol. 12(1), 7 (2019).
MedlineGoogle Scholar
65. Tomasik B, Bieńkowski M, Braun M, Popat S, Dziadziuszko R. Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – systematic review and meta-analysis. Lung Cancer 158, 97–106 (2021).
Medline CASGoogle Scholar
66. Yao J, Zhu X, Wu Z et al. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study. Cancer Med. 11(19), 3612–3622 (2022).
Medline CASGoogle Scholar
67. Kennedy LB, Salama A. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 70(2), 86–104 (2020).
MedlineGoogle Scholar
68. Govindan R, Ding L, Griffith M et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150(6), 1121–1134 (2012).
Medline CASGoogle Scholar
69. Wang GZ, Zhang L, Zhao XC et al. The aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat. Commun. 10(1), 1125 (2019).
Medline CASGoogle Scholar
70. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
Medline CASGoogle Scholar
71. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018–2028 (2015).
MedlineGoogle Scholar
72. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–128 (2015).
Medline CASGoogle Scholar
73. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465(7297), 473–477 (2010).
Medline CASGoogle Scholar
74. Li J, Zhu H, Sun L, Xu W, Wang X. Prognostic value of site-specific metastases in lung cancer: a population based study. J. Cancer 10(14), 3079–3086 (2019).
MedlineGoogle Scholar
75. Tamura T, Kurishima K, Nakazawa K et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol. Clin. Oncol. 3(1), 217–221 (2015).
MedlineGoogle Scholar
76. Blackburn SD, Shin H, Haining WN et al. Coregulation of CD8⁺ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10(1), 29–37 (2009).
Medline CASGoogle Scholar
77. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
Medline CASGoogle Scholar
78. Long GV, Atkinson V, Menzies AM, Lo S, McArthur GA. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC). J. Clin. Oncol. 35(Suppl. 15), S9508 (2017).
Google Scholar
79. Tawbi AH, Forsyth P, Algazi AP et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J. Clin. Oncol. 35(Suppl. 15), S9507 (2017).
Google Scholar
80. Huo G, Liu W, Chen P. Inhibitors of PD-1 in non-small cell lung cancer: a meta-analysis of clinical and molecular features. Front. Immunol. 13, 875093 (2022).
Medline CASGoogle Scholar
81. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3(7), 611–618 (2002).
Medline CASGoogle Scholar
82. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
Medline CASGoogle Scholar
83. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1(8), 1223–1225 (2012).
MedlineGoogle Scholar
84. Xu Y, Wang Q, Xie J et al. The predictive value of clinical and molecular characteristics or immunotherapy in non-small cell lung cancer: a meta-analysis of randomized controlled trials. Front. Oncol. 11, 732214 (2021).
MedlineGoogle Scholar
85. Qin BD, Jiao XD, Liu J et al. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Crit. Rev. Oncol. Hematol. 147, 102893 (2020).
MedlineGoogle Scholar
86. Shiroyama T, Suzuki H, Tamiya M et al. Clinical characteristics of liver metastasis in nivolumab-treated patients with non-small cell lung cancer. Anticancer Res. 38(8), 4723–4729 (2018).
Medline CASGoogle Scholar
87. Limmer A, Ohl J, Wingender G et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur. J. Immunol. 35(10), 2970–2981 (2005).
Medline CASGoogle Scholar
88. John B, Crispe IN. Passive and active mechanisms trap activated CD8⁺ T cells in the liver. J. Immunol. 172(9), 5222–5229 (2004).
Medline CASGoogle Scholar
89. Chae YK, Arya A, Iams W et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J. Immunother. Cancer 6(1), 39 (2018).
MedlineGoogle Scholar
90. Pocock SJ, Stone GW. The primary outcome fails – what next. N. Engl. J. Med. 375(9), 861–870 (2016).
MedlineGoogle Scholar
91. Peng S, Ying AF, Tai BC, Soo RA. A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. Transl. Lung Cancer Res. 9(4), 1124–1137 (2020).
Medline CASGoogle Scholar
92. Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am. J. Cancer Res. 10(1), 1–11 (2020).
Medline CASGoogle Scholar
93. Proto C, Ferrara R, Signorelli D et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat. Rev. 75, 39–51 (2019).
Medline CASGoogle Scholar
94. Verma V, Sharma G, Singh A. Immunotherapy in extensive small cell lung cancer. Exp. Hematol. Oncol. 8, 5 (2019).
MedlineGoogle Scholar
95. Hellmann MD, Rizvi NA, Goldman JW et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 18(1), 31–41 (2017).
Medline CASGoogle Scholar
96. Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 9(6), 499–506 (2017).
CASGoogle Scholar
97. Weber R, Fleming V, Hu X et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front. Immunol. 9, 1310 (2018).
MedlineGoogle Scholar
98. Shen X, Huang S, Xiao H et al. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies±other therapies in lung cancer: a systematic review and meta-analysis. Eur. J. Hosp. Pharm. 30(1), 3–8 (2021).
MedlineGoogle Scholar
99. De Marchi P, Leal LF, Duval da Silva V, da Silva E, Cordeiro de Lima VC, Reis RM. PD-L1 expression by tumor proportion score (TPS) and combined positive score (CPS) are similar in non-small cell lung cancer (NSCLC). J. Clin. Pathol. 74(11), 735–740 (2021).
MedlineGoogle Scholar
100. Haanen JB, Blank CU. Prognostic and predictive role of the tumor immune landscape. Q. J. Nucl. Med. Mol. Imaging 64(2), 143–151 (2020).
MedlineGoogle Scholar
101. Huang T, Chen X, Zhang H et al. Prognostic role of tumor mutational burden in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front. Oncol. 11, 706652 (2021).
MedlineGoogle Scholar
102. Yang Z, Wei S, Deng Y, Wang Z, Liu L. Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis. Jpn J. Clin. Oncol. 50(9), 1023–1031 (2020).
MedlineGoogle Scholar
103. Marcus L, Fashoyin-Aje LA, Donoghue M et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin. Cancer Res. 27(17), 4685–4689 (2021).
Medline CASGoogle Scholar
104. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69–74 (2015).
Medline CASGoogle Scholar
105. Addeo A, Friedlaender A, Banna GL, Weiss GJ. TMB or not TMB as a biomarker: that is the question. Crit. Rev. Oncol. Hematol. 163, 103374 (2021).
MedlineGoogle Scholar

Vol. 15, No. 3

Supplemental Materials

Metrics

Downloaded 127 times

History

Received 28 June 2022

Accepted 9 January 2023

Published online 23 January 2023

Published in print February 2023

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/imt-2022-0140

Author contributions

Conception and design: P Chen, GW Huo; collection and assembly of data: WJ Liu, SP Zhang; data analysis and interpretation: GW Huo, WJ Liu; manuscript writing: GW Huo, WJ Liu; final approval of the manuscript: all authors.

Financial & competing interests disclosure

This study was supported by funding from the Tianjin Major Disease Prevention and Control Science and Technology Project, Tianjin Municipal Science and Technology Bureau (18ZXDBSY00050). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download